Sigilon Therapeutics Inc

Sigilon Therapeutics seeks to develop functional cures for patients with a broad range of chronic diseases by harnessing the power of the human cell through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or other therapeutic molecules needed by patients living with chronic diseases such as lysosomal diseases and diabetes.

The engineered cells are encapsulated by Sigilon’s Afibromer™ biomaterials matrix, which is designed to shield them from immune rejection. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

For many years, researchers have investigated cell and gene therapies as potential replacement therapies for severe chronic diseases. Despite major advancements in the field, these approaches carry a number of limitations including immune rejection, limited eligibility, durability and variability challenges, inability to re-dose and high manufacturing costs. To address these drawbacks, we developed our novel Shielded Living Therapeutics™ (SLTx) platform, which we believe has the potential to result in functional cures for patients with a wide range of chronic diseases.



Leveraging the modularity of our SLTx platform, we have developed a growing pipeline of non-viral engineered cell based product candidates that have the potential to produce a wide range of missing or deficient therapeutic molecules . Moreover, our product candidates are designed to be off-the-shelf, durable, controllable and redosable, without requiring modification of the patient’s genes.



We are presently focused on two prioritized therapeutic areas: lysosomal and endocrine diseases. While the diseases we aim to treat are quite different, our products candidates themselves are generated through three common elements: the cell, the sphere, and our streamlined manufacturing process.